First-line therapy for non-transplant eligible patients with multiple myeloma: direct and adjusted indirect comparison of treatment regimens on the existing market in Germany
Crossref DOI link: https://doi.org/10.1007/s00228-015-1998-5
Published Online: 2015-12-16
Published Print: 2016-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kuhr, Kathrin
Wirth, Daniel
Srivastava, Kunal
Lehmacher, Walter
Hellmich, Martin
Funding for this research was provided by:
Janssen-Cilag GmbH, Neuss, Germany
Text and Data Mining valid from 2015-12-16